Weiss Ratings Reiterates "Sell (D-)" Rating for Dominari (NASDAQ:DOMH)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Dominari (NASDAQ:DOMH), indicating ongoing skepticism about the company's stock performance.
• In contrast, Wall Street Zen upgraded Dominari from a "sell" to a "buy" rating just a day prior, reflecting mixed analyst sentiment regarding the stock.
• Dominari reported a substantial loss of ($1.02) per share for the recent quarter, highlighting its financial struggles with a net margin of -36.01%.

Dominari (NASDAQ:DOMH - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of Dominari from a "sell" rating to a "buy" rating in a research note on Saturday, August 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of "Sell".

Dominari Trading Down 2.2%

Dominari stock opened at $5.86 on Friday. Dominari has a 1-year low of $0.83 and a 1-year high of $13.58. The firm has a market capitalization of $93.76 million, a price-to-earnings ratio of -2.47 and a beta of 0.75. The firm's fifty day moving average price is $6.33 and its two-hundred day moving average price is $5.51.

Dominari (NASDAQ:DOMH - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($1.02) earnings per share for the quarter. Dominari had a negative net margin of 36.01% and a negative return on equity of 94.32%. The business had revenue of $34.10 million during the quarter.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DOMH. Connective Capital Management LLC bought a new position in shares of Dominari during the second quarter valued at about $1,446,000. Jane Street Group LLC bought a new position in shares of Dominari during the second quarter valued at about $158,000. Magnus Financial Group LLC bought a new stake in Dominari in the second quarter worth about $136,000. Finally, Geode Capital Management LLC raised its position in Dominari by 2.9% in the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock worth $361,000 after acquiring an additional 1,866 shares during the period. 42.48% of the stock is owned by institutional investors.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.